1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

  • April 2016
  • -
  • La Merie Publishing
  • -
  • 74 pages

Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update


This Competitive Intelligence report about CD19-Targeted Therapeutics provides a competitor evaluation in the field of antibody- and T-cell-based therapeutics for the treatment of B-cell hematologic malignancies as of April 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


The report includes a compilation of currently active projects in research and development of antibodies and T-cells targeting CD19. In addition, the report lists company-specific R&D pipelines of CD19-Targeted Therapeutics. Competitor projects are listed in a tabular format providing information on:



  • Drug Codes,

  • Target / Mechanism of Action,

  • Class of Compound,

  • Company,

  • Product Category,

  • Indication,

  • R&D Stage and

  • additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


Table Of Contents

Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update


Table of Contents


1. CD19-Targeted Therapeutics:



  • Fc-Engineered CD19-Targeted Antibodies

  • CD19-Targeted Antibody-Drug Conjugates

  • CD19-Targeted Immunotoxin

  • Bispecific, CD19-Targeted and T-Cell Recruiting Monoclonal Antibodies

  • Other CD19-Targeted Bispecific Monoclonal Antibodes

  • Autologous CD19-Targeted Chimeric Antigen Receptor T-Cells

  • Allogeneic CD19-Targeted Chimeric Antigen Receptor T-Cells


2. Corporate CD19-Targeted Therapy Pipelines


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
T-Cell Immunotherapy Market (2nd Edition), 2017-2030

T-Cell Immunotherapy Market (2nd Edition), 2017-2030

  • $ 2449
  • Industry report
  • January 2017
  • by Roots Analysis Private Ltd.

INTRODUCTION The concept of immunotherapies dates back to the 18th century; however, since inception, the field has evolved tremendously and is currently cited as one of the most rapidly growing segments ...

 B-Cell Non-Hodgkin Lymphoma-Pipeline Insights, 2017

B-Cell Non-Hodgkin Lymphoma-Pipeline Insights, 2017

  • $ 1250
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s, “ B-Cell Non-Hodgkin Lymphoma-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the B-Cell Non-Hodgkin Lymphoma. ...

Stem Cell Transplantation Global Clinical Trials Review, H2, 2016

Stem Cell Transplantation Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • September 2016
  • by GlobalData

Stem Cell Transplantation Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Stem Cell Transplantation Global Clinical Trials Review, H2, 2016" provides an overview ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.